Pancreatic Cancer Research

ResearcherKanazawa UniversityActive in the last 2 years

Mitsuyoshi Okazaki

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0552-0297; OpenAlex author ID A5021109178. Sources: OpenAlex.

Their work

Papers
11 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
10
Papers, trials and grants by year

2018: 2 papers · 2019: 1 paper · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: 4 papers · 2025: none · 2026: 1 paper

Papers 11

  1. RAGE signaling inhibition prevents the malignant phenotypes of pancreatic ductal adenocarcinoma cells. Co-author DOI 10.1038/s41598-026-48913-5↗
  2. Clinical impacts of positive intraepithelial neoplasia at pancreatic transection margin in pancreatic cancer surgery. Co-author DOI 10.1016/j.pan.2024.02.005↗
  3. Morphology of the Dorsal Pancreatic Artery and Its Oncological Significance in Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000002327↗
  4. [Two Cases of Portal Vein Stent Placement for Portal Vein Stenosis Due to Recurrence of Pancreatic Cancer]. First author PMID 38449416↗
  5. Enhanced Germinal Center Reactions Within Tertiary Lymphoid Structures Following Neoadjuvant Chemotherapy and Intestinal Care-A Path to Robust Antitumor Immune… Co-author PMID 39571990↗
  6. Verification of Resectability Status for Pancreatic Cancer: Radiological and Pathological Analysis of Patients Undergoing Pancreatoduodenectomy With Combined R… Co-author DOI 10.1097/mpa.0000000000001964↗
  7. A phase I study of preoperative (neoadjuvant) chemotherapy with gemcitabine plus nab-paclitaxel for resectable pancreatic cancer. Co-author DOI 10.3892/mco.2020.2188↗
  8. [Intestinal Care Using L‒Glutamine Supplement and Probiotics Can Induce a Strong Anti‒Tumor Immune Response through the Induction of Mature Tertiary Lymphoid S… Co-author PMID 33976027↗
  9. Impact of Extravasated Platelet Activation and Podoplanin-positive Cancer-associated Fibroblasts in Pancreatic Cancer Stroma. Co-author DOI 10.21873/anticanres.13750↗
  10. Phase I study of third-line palliative chemotherapy with low dose paclitaxel for pancreatic cancer. First author DOI 10.3892/mco.2018.1579↗
  11. [A Case of Pathological Complete Response Induced by Preoperative Chemotherapy with Gemcitabine plus Nab-Paclitaxel in a Patient with Pancreatic Cancer on Hemo… Co-author PMID 30692318↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Isamu Makino · 11 shared papers, 2018–2026 · strength 1.81
  2. Shintaro Yagi · 5 shared papers, 2024–2026 · strength 1.20
  3. Tetsuo Ohta · 8 shared papers, 2018–2024 · strength 1.12
  4. Satoshi Takada · 4 shared papers, 2024–2026 · strength 0.89
  5. Hidehiro Tajima · 6 shared papers, 2018–2022 · strength 0.60
  6. Tomoharu Miyashita · 5 shared papers, 2018–2021 · strength 0.48
  7. Itasu Ninomiya · 5 shared papers, 2018–2022 · strength 0.43
  8. Hironori Minami · 1 shared paper, 2026 · strength 0.28
  9. Hirotaka Yuki · 1 shared paper, 2024 · strength 0.21
  10. Takahiro Kyuno · 1 shared paper, 2024 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.